2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Radiation Therapy, Workforce, Adverse Events, Artificial Intelligence (AI), Generative AI, Natural Language Processing, Biological Processes, Immune Mechanism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Infectious Diseases, Viral, Bacterial, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, CLL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

2721 Real-world outcomes and safety of frontline treatment strategies for CD5-positive large B-cell lymphoma

Siyuan Li, Min Lang2, Yan Zhang, MD3, Dao-Bin Zhou4
1 Peking Union Medical College Hospital, Beijing, China
2 Peking Union Medical College Hospital, Beijing, China
3 Peking Union Medical College Hospital, Beijing, China
4 Peking Union Medical College Hospital, Beijing, China

Background: CD5-positive large B-cell lymphoma (CD5+ LBCL) is an uncommon aggressive B-cell malignancy characterized by high-risk clinical features and unfavorable outcomes. The optimal frontline treatment strategy remains undefined. We evaluated the real-world effectiveness and safety of different frontline approaches in patients with newly diagnosed CD5+ LBCL.

Methods: We retrospectively included 45 previously untreated patients with CD5+ LBCL diagnosed at Peking Union Medical College Hospital between 2017 and 2024. According to their frontline treatment, patients were classified into an R-CHOP–like group (n=10), an intensified-treatment group receiving systemic methotrexate-containing or dose-intensified regimens (n=20), and a novel-agent group receiving regimens containing zanubrutinib or polatuzumab vedotin (n=15). Follow-up was conducted through December 31, 2025. End-of-treatment complete response (CR), progression-free survival (PFS), overall survival (OS), central nervous system (CNS) events, and treatment-related adverse events were evaluated. PFS was estimated using the Kaplan–Meier method and compared using the log-rank test, with Holm adjustment for pairwise comparisons.

Results: The median age was 61 years. Ann Arbor stage III–IV disease, elevated lactate dehydrogenase, extranodal involvement, bone marrow involvement, and baseline CNS involvement were present in 80.0%, 60.0%, 93.3%, 37.8%, and 15.6% of patients, respectively. Baseline distributions differed among the treatment groups: patients in the intensified-treatment group were younger (median age, 57 years vs 65 years in the R-CHOP–like group and 61 years in the novel-agent group; P=0.043), whereas treatment initiation in 2024 was more frequent in the novel-agent group (73.3% vs 20.0% and 10.0%, respectively; P<0.001). The overall CR rate was 75.6% (34/45), with rates of 50.0%, 80.0%, and 86.7% in the R-CHOP–like, intensified-treatment, and novel-agent groups, respectively (P=0.144). After a median follow-up of 18.3 months (range, 2.5–84.1), the estimated 2-year PFS rates were 46.7%, 60.3%, and 92.3%, respectively (overall log-rank P=0.039). The difference between the novel-agent and R-CHOP–like groups remained significant after Holm adjustment (P=0.045). The estimated 2-year OS rate for the entire cohort was 88.9%, and median OS was not reached. Among 38 patients without baseline CNS involvement, 4 (10.5%) subsequently developed CNS relapse or progression. Febrile neutropenia occurred in 30.0%, 55.0%, and 20.0% of patients in the three groups, respectively (P=0.104).

Conclusions: Patients with newly diagnosed CD5+ LBCL had prominent high-risk clinical features, and disease control with R-CHOP–like therapy remained suboptimal. Frontline regimens containing zanubrutinib or polatuzumab vedotin produced numerically higher CR rates and promising early PFS, supporting their further evaluation as potential frontline options for CD5+ LBCL. Treatment intensification did not show a clear PFS advantage and was associated with a numerically higher incidence of febrile neutropenia. These findings should be interpreted cautiously because of the small sample size, nonrandomized treatment selection, baseline and treatment-era imbalances, and shorter follow-up in the novel-agent group.

Siyuan Li: No relevant conflicts of interest to declare.